M&M Kelly has introduced three structured advisory engagements for life-sciences leadership teams and investors, covering AI governance readiness, competitive disruption risk, and due diligence evaluation of pharma and biotech companies ahead of capital decisions.
-- M&M Kelly, an AI transformation advisory firm, has announced three named advisory engagements for pharmaceutical, biotech, and life-sciences organizations. The offerings are designed to give leadership teams and investors a structured framework for evaluating AI governance, organizational readiness, and competitive exposure before capital and governance decisions are made. Each engagement is defined and scoped, developed in response to the specific pressures facing life-sciences companies today.
For more details, visit https://mandmkelly.com/life-sciences
Life-sciences investors face a layered challenge when evaluating an AI-enabled company: they must assess how a target uses AI internally, how mature its governance is, and how exposed its business model may be to competitors. The regulatory environment in pharma and biotech can raise the cost of a poor AI decision well beyond what other industries typically face. The OECD’s Due Diligence Guidance for Responsible AI, published in February 2026, provides a framework for including AI-related risks in portfolio assessments and calls for a clear rationale behind AI adoption decisions.
M&M Kelly designed its assessments to surface these considerations for the people responsible for capital and governance decisions. The Life Sciences AI Readiness Assessment, a four-to-six-week engagement, examines leadership alignment, decision authority, use-case priorities, governance, and strategic direction.
M&M Kelly notes that most life-sciences organizations make AI decisions without first confirming that leadership agrees on what AI is supposed to do, where experimentation ends, and compliance begins, or who holds the authority to approve a given initiative. The assessment is designed to establish that internal alignment before further resources are committed.
That assessment is followed by a second engagement: the AI Disruption Assessment, a three-to-four-week process that looks outward at what AI may enable for competitors, patients, researchers, and communities operating outside established institutions.
That outward-facing view feeds directly into the firm’s due diligence offering for investors. Life Sciences AI Due Diligence, a two-to-three-week engagement, is intended for PE/VC firms, family offices, strategic acquirers, and board governance committees evaluating pharmaceutical, biotech, and life-sciences companies. It assesses internal AI capability, governance, risk exposure, competitive positioning, and exposure to non-institutional innovation, and delivers a board briefing document alongside a presentation.
Together, the three engagements give investors and boards a more complete picture of a target company before capital is committed. Those interested can schedule a conversation with M&M Kelly through the form on the company’s website.
For more, visit https://mandmkelly.com/
Contact Info:
Name: David R. Lusk
Email: Send Email
Organization: M&M Kelly
Address: 1234 Advisory Circle, Charlotte, North Carolina 29716, United States
Phone: +1-404-924-9241
Website: https://mandmkelly.com/
Source: NewsNetwork
Release ID: 89209289
In case of detection of errors, concerns, or irregularities in the content provided in this press release, or if there is a need for a press release takedown, we strongly encourage you to reach out promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for immediate assistance within 8 hours – resolving identified issues diligently or guiding you through the removal process. We take great pride in delivering reliable and precise information to our valued readers.
